Sign Up to like & get
recommendations!
0
Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04132-x
Abstract: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the United States in combination with low-dose cytarabine (LDAC) to treat patients with newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive…
read more here.
Keywords:
patients newly;
glasdegib;
newly diagnosed;
treatment ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-01084-2
Abstract: A strength of Evolving treatment patterns and outcomes in older AML: changing everything to change nothing? is documenting the suspected increasing use of non-intensive induction therapy in persons age ≥60 years from 1% 1999 to…
read more here.
Keywords:
trial;
use;
ldac;
value ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18560
Abstract: The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low‐dose cytarabine (LDAC) or venetoclax‐based regimens. Progress is being made, however, for subgroups…
read more here.
Keywords:
dose ara;
ldac;
low dose;
bct 100 ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Nutrients"
DOI: 10.3390/nu11092256
Abstract: Taiwanofungus camphoratus is a rare and valuable medicinal mushroom indigenous to Taiwan. It has traditionally been used to promote good health. This study aimed to explore the immunomodulatory effects of “Leader Deluxe Taiwanofungus camphoratus capsule”…
read more here.
Keywords:
fruiting body;
body extract;
ldac;
immunomodulatory effects ... See more keywords